Delivery Order SPE2DB22D2006-SPE2DB26FV5XW
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,936.96 delivery order on July 23, 2025, for XYOSTED 75 mg/0.5 mL auto-injector units (0.5 mL). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,062.43 to AmerisourceBergen Drug Corp for the supply of XYOSTED 50 mg/0.5 ml auto-injector units. The contract is a firm fixed price delivery order with an ultimate completion date of August 22, 2025, awarded on August 21, 2025, with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,158.00 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies. The contract, awarded on September 22, 2025, represents a firm fixed-price delivery order with an ultimate completion date of September 23, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was not set-aside and was competitively awarded, consistent with...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, with an ultimate completion date of July 21, 2025. This non-set-aside competitively awarded contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies, valued at $1,006.78 under a firm fixed-price arrangement. The award, issued on June 30, 2025, with an ultimate completion date of July 1, 2025, represents a non-competitive delivery order. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,629.66 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies, with an ultimate completion date of October 16, 2025. This competitive award, issued on October 15, 2025, utilizes firm fixed pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,597.81 on September 23, 2025, for XYOSTED 50 MG/0.5 ML auto-injector supplies (0.5 ML). The contract is structured as a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded procurement. Performance will occur at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of September 24, 2025. This award is a child...
- The Defense Logistics Agency awarded a $1,358.05 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector units. This non-set-aside contract is classified as a firm fixed price delivery order with an ultimate completion date of August 28, 2025, and was awarded on August 27, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,293.84 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same municipality....
- The Defense Logistics Agency (DLA) awarded a $1,751.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies on September 2, 2025, with completion targeted for September 3, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle active through December...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB26FV5XWDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,131.13 to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector units, with an ultimate completion date of October 31, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a competitively awarded delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location in the same municipality. This delivery order is a child contract under AmerisourceBergen's prime IDC designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The SPE2DX contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications and medical supplies to military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. This particular order for XYOSTED, a testosterone replacement therapy auto-injector, exemplifies the company's role as a critical vendor for specialized pharmaceutical products supporting federal medical procurement needs. AmerisourceBergen's extensive portfolio of federal contracts demonstrates its capability to deliver diverse therapeutic products ranging from specialty medications to generic drugs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 10/30/25 |